SANOFI PRESENTATION Brussels - March 27, 2018 Arnaud Delépine, Associate VP, Investor Relations

Page created by Casey Norton
 
CONTINUE READING
SANOFI PRESENTATION Brussels - March 27, 2018 Arnaud Delépine, Associate VP, Investor Relations
SANOFI PRESENTATION
          Brussels – March 27, 2018
Arnaud Delépine, Associate VP, Investor Relations

                                                    1
SANOFI PRESENTATION Brussels - March 27, 2018 Arnaud Delépine, Associate VP, Investor Relations
Forward-Looking Statements
  This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
  Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their
  underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events,
  operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are
  generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although
  Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned
  that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and
  generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or
  implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the
  uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory
  authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be
  filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or
  commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially
  successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth
  opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and
  the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of
  cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or
  identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary
  Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2017. Other
  than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or
  statements.

                                                                                                                                                    2
SANOFI PRESENTATION Brussels - March 27, 2018 Arnaud Delépine, Associate VP, Investor Relations
Sanofi: a Diversified Healthcare Leader

                   By activity              By geographic region

                       Pharmacy            Europe                   United States
                     €29,954M             €9,525M                  €11,855M
  2017 sales             85.4 %            27.2 %                      33.8 %

€35,055M
                        Vaccines      Emerging Markets             Rest of the World

                      €5,101M             €10,258M                  €3,417M
                         14.6 %             29.3 %                      9.7 %

                                                                                    3
SANOFI PRESENTATION Brussels - March 27, 2018 Arnaud Delépine, Associate VP, Investor Relations
Continued Progress on Sanofi’s Strategic
Transformation

    Reshape portfolio                               Execute launches                                       Drive simplification                                Sustain innovation
• Acquisition of Bioverativ:                   • Dupixent®: launch success                          • Fitusiran: global rights                           • Cemiplimab et dupilumab(3):
  strenghtens leadership in rare                                                                      obtained in hemophilia(4)                            Acceleration and expansion of
                                               • Kevzara® : steady share gains
  diseases                                                                                                                                                 their development
                                                 in the U.S.                                        • Focused organization
• Acquisition of Ablynx: expands                                                                      delivered cost savings of                          • Acquisition of Bioverativ: brings
                                               • Praluent® and Soliqua®
  rare blood disorder franchise(1)               100/33/SuliquaTM: launches                           €1.5bn since 2015, one year                          late-stage R&D pipeline
                                                                                                      ahead of plan
• Divestiture of EU Generics                     progressing slower than                                                                                 • Acquisition of Ablynx(1):
  expected in 2018(2)                            originally anticipated                                                                                    transformative Nanobody®
                                                                                                                                                           technology platform
• Acquisition of Protein Sciences
  in Vaccines

                   (1) Subject to the completion of the Ablynx acquisition announced on January 29, 2018      (3) In collaboration with Regeneron
                   (2) Following completion of the dialogue with social partners                              (4) Alnylam will receive royalties based on net sales of fitusiran products   4
SANOFI PRESENTATION Brussels - March 27, 2018 Arnaud Delépine, Associate VP, Investor Relations
Financial Performance in 2017

                 Sales: €35,055M
                                                    Gross margin
                Gross Profit: €24,759M
                                                      70.6 %
                                  Selling &       R&D / Sales ration
        R&D
                              general expenses
      €5,472M                                         15.6 %
                                 €10,058M
                                                  Business operating
        Business operating income: €9,343M             margin
                                                      26.7 %
        Tax                  Financial expenses
      €2,106M                      €273M

                                                     Net margin
       Business net income: €6,964M
                                                      19.9 %

                                                                       5
SANOFI PRESENTATION Brussels - March 27, 2018 Arnaud Delépine, Associate VP, Investor Relations
2017 EPS Broadly Stable In-Line with Expectations

                                                    Company Sales                               Business EPS

                                                                        €35,055M               €5.68
                                               €33,821M                                                  €5.54

                                                                                  +0.5%                        -0.4%
                                                                                                                 at CER
                                                                                   at CER/CS

                                                    2016                    2017               2016      2017

       CER= Constant Exchange Rates
       CS= Constant Structure, adjusted for BI CHC business, termination of SPMSD and others
                                                                                                                          6
SANOFI PRESENTATION Brussels - March 27, 2018 Arnaud Delépine, Associate VP, Investor Relations
2018 Financial Guidance

 FY 2018

 Business EPS                                                             +2% to +5% at CER(1,2,3)

 FW impact on Business EPS                                                           -3% to -4%(4)
                                                                   based on December 2017 average exchange rates

           (1)   Including the anticipated contribution from the recently announced acquisitions
           (2)   Compared to FY2017 and barring major unforeseen adverse events
           (3)   FY 2017 Business EPS of €5.54
                                                                                                                   7
           (4)   Difference between variation on a reported basis and variation at CER
SANOFI PRESENTATION Brussels - March 27, 2018 Arnaud Delépine, Associate VP, Investor Relations
An Organization Based on Five Global Business Units

                             Sanofi Pasteur
                                Vaccines

                                                    Sanofi Genzyme
Consumer Healthcare
                                                      Specialty Care

                                  5
                                GBUs

       General Medicines &                      Diabetes &
        Emerging Markets                      Cardiovascular

                                                                       8
SANOFI PRESENTATION Brussels - March 27, 2018 Arnaud Delépine, Associate VP, Investor Relations
Sanofi Genzyme – Speciality Care
Success of the New Immunology Franchise
                                                                             Global Specialty Care
                                                                               Franchise Sales
                                      Immunology
                                      Successful launch of Dupixent®              6,678 M€
                                                                               19% of company sales
                                      Kevzara® launch progressing well
                                      Multiple Sclerosis
                                      Strong, growing franchise
                                      Rare Diseases                              +14.5%
                                      Acquisitions strengthen leadership             at CER

                                      position
                                                                                                Immunology
                                      Oncology                                                  Multiple Sclerosis
                                      Significant expansion of development
                                                                                                Rare Diseases
                                      pipeline
                                                                                                Oncology

                                                                              2017

       CER= Constant Exchange Rates                                                                             9
SANOFI PRESENTATION Brussels - March 27, 2018 Arnaud Delépine, Associate VP, Investor Relations
Dupixent®: Global Roll-Out in Atopic Dermatitis in 2018
                                                                           2017 Launches and 2018 Expected Launches(2)

                                                                                  H1 2017                            H2 2017                         H1 2018                            H2 2018
     IGA 4                          IGA 1

   Pictures of a patient before and after treatment with
                       dupilumab (1)                                                                                                                     + 8 Emerging Market
                                                                                                                                                              countries

                                                                           2017 Sales: €219M
             (1) For illustration purposes only. Images are taken from one patient at baseline (left) and at 16 weeks (right). Results were not representative of all patients and individual results did vary
             (2) Launched in the U.S. in April 2017, Germany in December 2017, the Netherlands in January 2018 and Denmark in February 2018                                                                      10
Dupixent®: Global Launch Opportunities in Multiple Diseases
                                                                             Growth Opportunities across Diseases,
                                                                               Geographies and Demographics(1)
• Dupilumab expected to be a key growth
  driver with significant commercial potential                               ILLUSTRATIVE
  in multiple diseases(1)                                                                                               COPD

• FDA to review Dupixent® (dupilumab) as                                                                             Allergies

  potential treatment for moderate-to-severe                                                                       Eosinophilic Esophagitis
  asthma                                                                                                        Nasal Polyposis

                                                                                                                Pediatric AD

                                                                                                          Adult/adolescent Asthma Japan/RoW

                                                                                                   Adult/adolescent Asthma EU

                                                                                                Adult/adolescent Asthma U.S.

                                                                                         Adult AD in Japan and RoW

                                                                                     Adult AD in EU

                                                                             Adult AD in U.S.

                                                                                                               Time
             (1) If approved in indications by applicable Health Authority
             COPD= Chronic Obstructive Pulmonary Disease
             AD= Atopic Dermatitis
                                                                                                                                              11
Kevzara® - A New Treatment for Patients with Moderately to
Severely Active Rheumatoid Arthritis

                                                  A major market with very important unmet needs
                                                  •   1.3 million people in the United States
                                                  •   2.9 million people in Europe

                                                  Marketed in the U.S. since May 2017 and currently being
                                                  launched in Europe

       Kevzara® in collaboration with Regeneron                                                             12
Strong Growth of the Multiple Sclerosis Franchise in 2017

                  Sales Evolution

                                             €2,041M

                                 €1,720M                        +13.6%
                                                                at CER
                                                     +20.8%
                                                       at CER
                 €1,114M
                                                                +23.2%
                                                                at CER
                                              1 295 M€

     €467M

     2014          2015               2016    2017

        CER= Constant Echange Rates                                      13
Sanofi Pasteur - Vaccines
                                                                                            Global Vaccines
                                                                                            Franchise Sales
                                      Leading vaccines in 5 areas:
                                                                                                €5,101M
                                      •   Influenza                                         14.6% of company sales
                                      •   Pediatric Combinations
                                      •   Meningitis
                                      •   Adult Boosters                                +8.3%
                                                                                        at CER/CS

                                      •   Travelers and other vaccines for endemic
                                          countries
                                                                                                      Pediatric Combinations
                                      A strenghtened pipeline with the
                                                                                                      Influenza Vaccines
                                      acquisition of Protein Sciences
                                                                                                      Meningitis/Pneumo
                                      Impact from the      Dengvaxia®   label                         Adult Boosters
                                      update                                                          Travel/Endemic
                                                                                                      Other
                                                                                     2017

       CER= Constant Exchange Rates
       CS= Constant Structure                                                                                              14
Protein Sciences Broadens Our Leading Flu Vaccines Portfolio With
Flublok®(1)
                                                                                       Growth driven by
                                                                              product differentiation following age

                                                                                                                Better efficacy
                                                              65y old
                                                                                        Fluzone HD TIV                           Fluzone HD QIV

                                                                                               Better efficacy                            -43%
                                                              50y old                                                              Cumulative confirmed Flu
                                                                                                   Flublok                          cases compared with
                                                                                                                                  Traditional QIV vaccines(2,3)

                                                                                                          Change standard of care
                                                              6m old                       Fluzone TIV                            Fluzone QIV
                                                                                           VaxiGrip TIV                           VaxiGrip QIV

       HD= High-Dose
       (1) The Only FDA approved recombinant protein-based influenza vaccine approved for all adults 18 and older
       (2) Source: Full prescribing information                                                                                                                   15
       (3) http://www.nejm.org/doi/full/10.1056/NEJMoa1608862
Diabetes and Cardiovascular Diseases
                                                                                      Global DCV
                                                                                    Franchise Sales
                                                                                          €6,905M
                                                                                   19.7% of company sales

                                               Diabetes Franchise
                                                                                    -0.6%
                                               Global sales down 11.1 %
                                               at CER in 2017
                                                                               +11.6%
                                               ● U.S. diabetes sales decline                   -20.2%
                                                 partially offset by strong                                 United States

                                                 performance in Emerging          +0.1%                     Europe

                                                 Markets                                                    Emerging Markets
                                                                                                            Rest of the World

                                                                                        2017

       All growth rates at Constant Exchange Rates (CER)                                                                    16
Odyssey Outcomes: Praluent® Significantly Reduces Risk of
Cardiovascular Events in High-Risk Patients

    Praluent® reduced by 15%(1) the
    risk of major adverse                                                         Approved in more than

    cardiovascular events                                                         60 countries

   Reduction of all cause mortality by
    15%(2)

   A more pronounced effect
    observed in patients with baseline                                            Focus on patients with the
    LDL-C levels ≥ 100 mg/dL                                                      greatest health risk

           Praluent® (alirocumab) is developped in collaboration with Regeneron
           (1) HR=0.85, IC : 0.78-0.93, p=0.0003
           (2) HR=0.85; IC: 0.73-0.98, nominal p value = 0.026                                                 17
           For more information: consult the press release from March 10, 2018
Sanofi is One of the Top 3 Players in Consumer Healthcare
                                                                                Global CHC
                               Integration of the Boehringer Ingelheim CHC    Franchise Sales
                               business being finalized
                                                                                 €4,832M
                                                                             13.8 % of company sales

                               Allergies, Cough & Cold           Pain

                                                                                    +2.1%
                                                                                    at CER/CS

                                                                                                Allergies
                                      Digestive              Nutritionals                       Pain
                                                                                                Digestive
                                                                                                Nutritionals
                                                                                                Other

                                                                             2017

       CER= Constant Exchange Rates
       CS= Constant Structure                                                                               18
General Medicines & Emerging Markets: Leading Position
in Emerging Countries Due to an Adapted Product Portfolio
                                                                    2017 Global GEM Business Unit Sales
                                                                                 €14,048M
                                                                           40% of company sales

                                  Emerging Markets(1)
                                  Sanofi ranks #1(2)
                                  Supported by strong growth of sales in China:
                                  €2.2Bn : +15.1%(3)

                                  Established Products
                                  Accounting for nearly one third of company sales

       (1) World excluding U.S., Canada, Europe, Japan, South Korea, Australia, New Zealand and Puerto Rico
       (2) Market share (without Vaccines), IMS MIDAS | FY 2017
       (3) At Constant Exchange Rates and Constant Structure
                                                                                                              19
Sanofi is #1 in Emerging Markets

                              More than 7 billion people

                              Aging population

                              Rapid emergence of a middle class

                              Improving access to healthcare

                              Growing GDP health expenses

                Emerging Markets up +6.0% in FY 2017

                                                                  20
Strategically and Financially Compelling M&A to Enhance
Sanofi’s Growth Profile and Create Value

                                                                                                                             Build                   Immediate
                                                                                                   Value                                Strengthen
                                                                           Value                          (1)              Leadership                   EPS
                                                                                                  Creation                               Pipeline              (2)
                                                                                                                            Position                  Accretion

               Transforming the lives of
               people with hemophilia, cold
               agglutinin disease and other                            $11.6 bn                                                                       
               rare blood disorders

               Nanobody technology to
               develop therapeutics in
               areas of high unmet medical
                                                                        €3.9 bn                                                                       ~
               need

       (1) ROIC>WACC in 3 to 5 years
       (2) Business EPS is a non-GAAP financial measure (see appendix to Sanofi quarterly financial release definitions)                                      21
Bioverativ: a Leading Hemophilia Portfolio, a New Platform in
Other Rare Blood Disorders

                                       U.S. biotechnology company, ~450 employees
                                       2017 Revenues: $1,168M +31.7%

                                       Leadership position in the large hemophilia market with two
                                       marketed products:
                                                             (1)                      (2)

                                       R&D : pipeline includes candidates in cold agglutinin disease,
                                       hemophilia and other rare blood disorders

                                       Complementary fit with fitusiran; maximizes commercial
                                       potential of current and future products

       (1) Treatment in hemophilia A
       (2) Treatment in hemophilia B                                                                    22
Ablynx: Provides a Leading Platform Technology and
Enhances our Late-Stage Pipeline

            1 Innovative Nanobody® platform strengthens Sanofi’s multi-targeting R&D strategy

            2 Caplacizumab expands rare blood disorders franchise following Bioverativ deal

               Complementary mid-stage and pre-clinical programs: hematology, inflammation,
            3 immuno-oncology, respiratory diseases

            4 Expected to be neutral to Business EPS in 2018 and 2019

                                                                                              23
Sanofi Research and Development

                        70
 projects in development for NMEs                                                                             potential submissions in
                                                                                                                                      7
      or additional indications(1)                                                                                next 15 months

                              7                                                                                                >10
        NME and Vaccine                                                                                          pivotal study starts in
      approvals since 2015(2)                                                                                       next 12 months

        (1) Includes 4 Phase 1 products and 1 Phase 2 product for which Sanofi has opt-in rights but has not exercised these rights
        (2) Adlyxin®, Dengvaxia®, Dupixent®, Kevzara®, Praluent®, Soliqua™ /Suliqua™ 100/33, Toujeo®                                       24
7 Potential Submissions(1) for New Products or Additional
Indications Over Next 15 Months
                                                            Planned Submissions
                                                                                                                                                 Men Quad TT
                                                                                                           sBLA,                                 2nd generation
                                          sBLA,                                                             AD,                                  meningococcal
          NDA,                           ODYSSEY                                                        adolescents                             ACYW conjugate
     Type 1 Diabetes                      CVOT                                                            12-
New Wave of Pivotal Study Starts Expected in 2018

  dupilumab(1)                   • COPD                                                           isatuximab                              • 1L MM SCT eligible
   Anti-IL4Rα mAb                • Eosinophilic Esophagitis                                       Anti-CD38 mAb                           • 1L MM SCT ineligible

   venglustat(2)                 • Autosomal dominant
                                   polycystic kidney
                                                                                              alemtuzumab                                • Primary Progressive MS
  Oral GCS inhibitor
                                   disease (ADPKD)

  SAR425899
    GLP-1/GCR                     • Obesity
                                                                                               cemiplimab(1)                             • 1st line NSCLC
    dual agonist

 efpeglenatide(3)
    Once-weekly                   • Type 2 Diabetes
                                                                                             mavacamten(4)                               • Obstructive Hypertrophic
     GLP-1RA                                                                                                                               Cardiomyopathy

         COPD= Chronic Obstructive Pulmonary Disease; NSCLC= Non-Small Cell Lung Cancer   (3) Collaboration with Hanmi
         (1) Collaboration with Regeneron                                                 (4) Collaboration with Myokardia. Sanofi will lead ex-U.S. regulatory and commercial   26
         (2) Phase 2/3 registrational study                                                   activities to mavacamten program where it has ex-U.S. commercialization rights
Sanofi Share Performance vs. Pharma Company Peers
since January 2018, in Euro
                                   Stock Performance since January 1st, 2018 in €
                                                  CAC40: -1.4%
                                                                                                         13.8%
                                                         Median      Average
                                                          -5.9%       -4.1%                       5.6%

                                                                                          -0.1%
                                                                                  -2.0%
                                                                          -3.3%
                                                                  -4.8%
                                                         -5.9%
                                                 -8.1%
         -9.5%     -9.3%         -9.3%   -9.0%
-11.1%

             Source: Bloomberg                                                                              27
Sector Rotation from Defensive to More Cyclical Sectors

                                                                                                      14.1%   14.8%

                                                                                               9.5%
                                                    Pharma
                                                                                        4.3%
                                                                                 3.6%
                                                         1.1%

                                  -3.3%
           -5.8%
 -8.0%

         S&P Sectors since Sept 29, 2017 – source Nasdaq – as of March 1, 2018                                        28
The Dividend is a Core Part of our Value Proposition
to Shareholders
                                 Evolution of Dividend

                                                          €2.96 €3.03
                            €2.65 €2.77 €2.80 €2.85 €2.93
                €2.40 €2.50
        €2.20

        2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

 •   Proposed dividend of €3.03 per share for 2017 financial year(1)
 •   24th consecutive year of dividend increase

             (1) Submitted for approval by shareholders at the Annual General Meeting on May 2, 2018   29
An Active Communication with our Individual Shareholders

Your publications
                                                      SlideShare
•   Shareholder Handbook
•   Letter to Shareholders
•   Fact Sheet                                         YouTube

                                                       LinkedIn
Online information

•   www.sanofi.com/shareholders
•   Sanofi IR mobile app                               Twitter
•   Social Media

                                                                  30
Meetings with Shareholders
         Meetings planned in 2018                        Shareholders Committee
                             Bruxelles
                     Reims

                 Paris
                             Nancy

     Nantes

                          Lyon

                                     Nice

                                            •   4 events planned in 2018
 •   Annual General Meeting 2018            •   Visit of Marcy-l’Etoile Sanofi Pasteur industrial site
     •    May 2: Paris
                                            •   Meetings with management and the Chairman
 •   Salon Actionaria 2018
     •    November 22 - 23: Paris

                                                                                                         31
Sanofi: Life is a Health Journey

                                   32
You can also read